Detalles de la búsqueda
1.
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics.
BMC Cancer
; 22(1): 732, 2022 Jul 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35790916
2.
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 379(21): 2027-2039, 2018 11 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-30280657
3.
Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.
BMC Cancer
; 21(1): 230, 2021 Mar 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33676426
4.
Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data.
BMC Cancer
; 21(1): 977, 2021 Aug 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-34465283
5.
Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors.
Cancer Immunol Immunother
; 68(3): 341-352, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30725206
6.
Lung cancer in Spanish women: The WORLD07 project.
Eur J Cancer Care (Engl)
; 28(1): e12941, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30277293
7.
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
Lancet
; 389(10072): 917-929, 2017 03 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28126333
8.
Lung Cancer in Never-Smoking Women: A Sub-Analysis of the Spanish Female-Specific Database WORLD07.
Cancer Invest
; 35(5): 358-365, 2017 May 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-28350480
9.
Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel.
Future Oncol
; 11(2): 267-77, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25236437
10.
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.
J Clin Oncol
; 42(12): 1350-1356, 2024 Apr 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38324744
11.
Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients.
Arch Bronconeumol
; 60(2): 88-94, 2024 Feb.
Artículo
en Inglés, Español
| MEDLINE | ID: mdl-38160163
12.
Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry.
Lung Cancer
; 190: 107513, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38432027
13.
Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP.
Clin Transl Oncol
; 26(7): 1647-1663, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38530556
14.
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
Clin Lung Cancer
; 25(3): 233-243.e8, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38105153
15.
Spatially preserved multi-region transcriptomic subtyping and biomarkers of chemoimmunotherapy outcome in extensive-stage small cell lung cancer.
Clin Cancer Res
; 2024 Apr 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38630755
16.
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Lancet Oncol
; 13(3): 239-46, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22285168
17.
Cost-Effectiveness of Next-Generation Sequencing Versus Single-Gene Testing for the Molecular Diagnosis of Patients With Metastatic Non-Small-Cell Lung Cancer From the Perspective of Spanish Reference Centers.
JCO Precis Oncol
; 7: e2200546, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36862967
18.
SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022).
Clin Transl Oncol
; 25(9): 2679-2691, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37418123
19.
MET alterations in NSCLC-Current Perspectives and Future Challenges.
J Thorac Oncol
; 18(4): 419-435, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36441095
20.
Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges.
Nat Rev Clin Oncol
; 20(10): 664-677, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37488229